Kane Wishart is an associate in Weil’s Technology & IP Transactions practice and is based in New York. Mr. Wishart participates in advising Firm clients in a variety of matters relating to the licensing, acquisition, development, sale, use and commercial exploitation of intellectual property and technology.
Mr. Wishart has been part of the teams advising on the technology and intellectual property aspects of the following matters:
- AK Steel Corporation in its approximately $3 billion sale to Cleveland-Cliffs, Inc.
- Campbell Soup Company in its $2.2 billion sale of Campbell International, Inc.
- Eli Lilly and Company in its $1.1 billion acquisition of Dermira, Inc. and in a global licensing and research collaboration with Sitryx Therapeutics Limited
- Sanofi in its $350 million sale of its Seprafilm Adhesion Barrier and related assets to Baxter International Inc. and in its $2.5 billion acquisition of Synthorx, Inc.
Mr. Wishart received his LL.B. from Australian National University and his B.S., with Honors, from Monash University.